{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:23:53Z","timestamp":1790187833984,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["PB-PG-0815-20053"],"award-info":[{"award-number":["PB-PG-0815-20053"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pilot Feasibility Stud"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prescription methadone or buprenorphine enables people with opioid use disorder to stop heroin use safely while avoiding withdrawal. To ensure methadone is taken as prescribed and to prevent diversion onto the illicit market, people starting methadone take their daily dose under a pharmacist\u2019s supervision. Many patients miss their daily methadone dose risking withdrawal, craving for heroin and overdose due to loss of heroin tolerance. Contingency management (CM) can improve medication adherence, but remote delivery using technology may be resource-light and cost-effective. We developed an innovative way to deliver CM by mobile telephone. Software monitors patients\u2019 attendance and supervised methadone consumption through an internet self-login at the pharmacy and sends reinforcing text messages to patients\u2019 mobile telephones. A linked system sends medication adherence reports to prescribers and provides early warning alerts of missed doses. A pre-paid debit card system provides financial incentives.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cluster randomised controlled trial design was used to test the feasibility of conducting a future trial of mobile telephone CM to encourage adherence to supervised methadone in community pharmacies. Each cluster (drug service\/3 allied pharmacies) was randomly allocated to provide patient\u2019s presenting for a new episode of opiate agonist treatment (OAT) with either (a) mobile telephone text message CM, (b) mobile telephone text message reminders, or (c) no text messages. We assessed acceptability of the interventions, recruitment, and follow-up procedures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four drug clinics were approached and three recruited. Thirty-three pharmacists were approached and 9 recruited. Over 3 months, 173 individuals were screened and 10 enrolled. Few patients presented for OAT and high numbers were excluded due to receiving buprenorphine or not attending participating pharmacies. There was 96% consistency in recording medication adherence by self-login vs. pharmacy records. In focus groups, CM participants were positive about using self-login, the text messages, and debit card. Prescribers found weekly reporting, time saving, and allowed closer monitoring of patients. Pharmacists reported that the tablet device was easy to host.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Mobile telephone CM worked well, but a planned future trial will use modified eligibility criteria (existing OAT patients who regularly miss their methadone\/buprenorphine doses) and increase the number of participating pharmacies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The trial is retrospectively registered, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN58958179\">ISRCTN 58958179<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40814-020-00761-4","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T04:36:01Z","timestamp":1609994161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Mobile telephone delivered contingency management for encouraging adherence to supervised methadone consumption: feasibility study for an RCT of clinical and cost-effectiveness (TIES)"],"prefix":"10.1186","volume":"7","author":[{"given":"N.","family":"Metrebian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Shearer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Woolston-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Getty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"van der Waal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bijral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Strang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"761_CR1","volume-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence","author":"World Health Organization","year":"2009","unstructured":"World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 2009 WHO Libra."},{"key":"761_CR2","volume-title":"Chapter 16. Addictions, dependence and substance abuse. in Annual Report of the Chief Medical Officer","author":"J Strang","year":"2013","unstructured":"Strang J., Drummond C., McNeill A., Lader M., and Marsden J. Chapter 16. Addictions, dependence and substance abuse. in Annual Report of the Chief Medical Officer 2013, Public Mental Health Priorities."},{"key":"761_CR3","unstructured":"National Drug Evidence Centre, Statistics from the National Drug Treatment Monitoring System (NDTMS) 1st April 2016-31 March 2017. 2017."},{"key":"761_CR4","unstructured":"National Treatment Agency for Substance Misuse (NTA) From Access to Recovery: analysing six years of drug treatment data. NTA 2012. p. 5-7."},{"key":"761_CR5","volume-title":"Drug misuse and dependence: UK guidelines on clinical management. London Department of Health","author":"Department of Health and devolved administrations. Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group","year":"2017","unstructured":"Department of Health and devolved administrations. Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group, Drug misuse and dependence: UK guidelines on clinical management. London Department of Health (2017)."},{"key":"761_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1111\/j.1360-0443.2007.02016.x","volume":"102","author":"J Sheridan","year":"2007","unstructured":"Sheridan J, Manning V, Ridge G, Mayet S, Strang J. Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995-2005. Addiction. 2007;102:1824\u201330.","journal-title":"Addiction"},{"key":"761_CR7","volume-title":"Drug Misuse","author":"NICE National Institute for Care Excellence (NICE)","year":"2006","unstructured":"NICE National Institute for Care Excellence (NICE) Drug Misuse 2006."},{"key":"761_CR8","volume-title":"The behavior of organisms: an experimental analysis","author":"BF Skinner","year":"1938","unstructured":"Skinner BF. The behavior of organisms: an experimental analysis 1966, Skinner Foundation. Skinner, B. F. In: The behavior of organisms: an experimental analysis. Oxford: Appleton-Century; 1938."},{"key":"761_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1360-0443.2006.01311.x","volume":"101","author":"JP Lussier","year":"2006","unstructured":"Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction. 2006;101:192\u2013203.","journal-title":"Addiction"},{"key":"761_CR10","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/j.1360-0443.2006.01581.x","volume":"101","author":"M Prendergast","year":"2006","unstructured":"Prendergast M, Podus D, Finney J, Greenwall L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006;101:1546\u201360.","journal-title":"Addiction"},{"key":"761_CR11","doi-asserted-by":"crossref","unstructured":"Davis DR, Kurti AN, Skelly JM, Redner R, White TJ, Higgins ST. A review of the literature on contingency management in the treatment of substance misuse disorders 2009-2014. Preventive Medicine. 2016;92:36-46.","DOI":"10.1016\/j.ypmed.2016.08.008"},{"issue":"suppl","key":"761_CR12","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/j.ypmed.2012.04.017","volume":"55","author":"A DeFulio","year":"2012","unstructured":"DeFulio A, Silverman K. The use of incentives to reinforce medication adherence. NIH Public access. Prev Med. 2012;55(suppl):S86\u201394 DeFulio et al 2012.","journal-title":"Prev Med"},{"issue":"11","key":"761_CR13","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1111\/add.14725","volume":"114","author":"CA Getty","year":"2019","unstructured":"Getty CA, Morande A, Lynskey M, Weaver T, Metrebian N. Mobile telephone-delivered contingency management interventions promoting behaviour change in individuals with substance use disorders: a meta-analysis. Addiction. 2019;114(11):1915\u201325 Getty.","journal-title":"Addiction"},{"key":"761_CR14","unstructured":"Mindwave Ventures Ltd. TIES Project. King\u2019s College London and South London and Maudsley NHS Foundation Trust. 2017."},{"key":"761_CR15","first-page":"100506","volume-title":"Telephone delivered incentives for encouraging adherence to supervised methadone consumption (TIES): study protocol for a feasibility study for an RCT of clinical and cost effectiveness Contemporary Clinical Trials Communications","author":"N Metrebian","year":"2020","unstructured":"Metrebian N, Weaver T, Pilling S, Goldsmith K, Carr E, Shearer J, Woolston-Thomasa K, Tasa B, Getty CA, Cooper C, van der Waal R, Kelleher M, Finch E, Bijral P, Taylor D, Scott J, Strang J. Telephone delivered incentives for encouraging adherence to supervised methadone consumption (TIES): study protocol for a feasibility study for an RCT of clinical and cost effectiveness Contemporary Clinical Trials Communications, vol. 17; 2020. p. 100506."},{"key":"761_CR16","unstructured":"PharmOutcomes https:\/\/pharmoutcomes.org\/pharmoutcomes\/ [accessed 07.08.2020]."},{"key":"761_CR17","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1111\/j.1360-0443.1991.tb01706.x","volume":"86","author":"S Darke","year":"1991","unstructured":"Darke S, Heather N, Hall W, Ward J, Wodak A. Estimating drug consumption in opioid users: reliability and validity of a \u201crecent use\u201d episodes method. Br J Addiction. 1991;86:1311\u20136.","journal-title":"Br J Addiction"},{"key":"761_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","volume":"88","author":"JB Saunders","year":"1993","unstructured":"Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption. II. Addiction. 1993;88:791\u2013804.","journal-title":"Addiction"},{"key":"761_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361\u201370.","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"761_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1360-0443.1992.tb02719.x","volume":"87","author":"S Darke","year":"1992","unstructured":"Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multidimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Addiction. 1992;87(5):733\u201374217.","journal-title":"Addiction"},{"key":"761_CR21","unstructured":"Quality Metric Incorporated. Users Manual for the SF-36v2 Health Survey (3rd Edition). Received Optum PRO CoRE SF-36v2 on 10.06.2019. OptumInsight Life Sciences."},{"key":"761_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1192\/bjp.bp.112.111583","volume":"203","author":"S Byford","year":"2013","unstructured":"Byford S, et al. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. Br J Psychiatry. 2013;203:341\u20139.","journal-title":"Br J Psychiatry"},{"key":"761_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"issue":"2","key":"761_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/01.jom.0000052967.43131.51","volume":"45","author":"R Kessler","year":"2003","unstructured":"Kessler R, et al. The World Health Organisation Health and Work Performance Questionnaire. (HPQ). J Occupat Environ Med. 2003;45(2):156\u201374.","journal-title":"J Occupat Environ Med"},{"key":"761_CR25","doi-asserted-by":"publisher","unstructured":"Carreiroa S, Newcomba M, Leacha R, Ostrowskia S, Boudreauxa ED. Daniel Amanteb Current reporting of usability and impact of mHealth interventions for substance use disorder: a systematic review. Drug Alcohol Dependence. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108201.","DOI":"10.1016\/j.drugalcdep.2020.108201"},{"key":"761_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10461-014-0990-x","volume":"19","author":"BA Moore","year":"2015","unstructured":"Moore BA, Rosen MI, Wang Y, Shen J, Ablondi K, Sullivan A, et al. A remotely-delivered CBT and contingency management therapy for substance using people with HIV. AIDS Behav. 2015;19:156\u201362.","journal-title":"AIDS Behav"}],"container-title":["Pilot and Feasibility Studies"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-020-00761-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40814-020-00761-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-020-00761-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T04:42:00Z","timestamp":1609994520000},"score":1,"resource":{"primary":{"URL":"https:\/\/pilotfeasibilitystudies.biomedcentral.com\/articles\/10.1186\/s40814-020-00761-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1186\/s40814-020-00761-4","relation":{},"ISSN":["2055-5784"],"issn-type":[{"value":"2055-5784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"11 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial was reviewed by the London South East Research Ethics Committee and received a favourable opinion on 23 November 2018. All participants provided informed consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JStr and SP have contributed to UK guidelines on the potential role of contingency management in the management of opioid addiction (NICE, 2007; convened by SP, chaired by JStr). SP receives funding from NICE for the production of clinical guidelines. JS has chaired the broader-scope pan-UK working group preparing the 2017 and 2007 Orange Guidelines for the UK Departments of Health and Social Care, providing guidance on management and treatment of drug dependence and misuse, including guidance on possible inclusion of contingency management. JSc was a member of this group.JStr is a researcher and clinician who, through his university, has worked with various pharmaceutical companies to identify new or improved treatments and his employer (King\u2019s College London) has received grants, travel costs, and\/or consultancy payments from companies including, past 3\u2009years, Indivior, Mundipharma, Camurus, Molteni Farma, and Accord. JStr has also worked with various drug policy organisations and advisory bodies including the Society for the Study of Addiction (SSA), and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).JStr and KG are supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King\u2019s College London. JStr is an NIHR Senior Investigator. For a fuller account, see JStr\u2019s web-page at NM, through her employer (King\u2019s College London), has received a grant from a pharmaceutical company MundiPharma Research Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}